Identifying the right treatment plan is one of the many challenges faced by mesothelioma patients and their physicians. Those whose tumors are operable need to decide whether to pursue an aggressive form of surgery that removes the affected lung or to go with a less invasive procedure. A report issued today suggests that those who
Dr. John D. Mitchell is the Chief of General Thoracic Surgery within the Division of Cardiothoracic Surgery at the University of Colorado and the CU Cancer Center. He has extensive experience in treating cancers of the lungs, including malignant pleural mesothelioma, and focuses his research on lung cancer, surgical treatment of lung infection, and lung
Dr. Camidge is a thoracic oncologist at the University of Colorado. He has been the Director of CU’s Thoracic Oncology Clinical Program and Clinical Research Program since 2007. His approach to treating malignant pleural mesothelioma and lung cancer focuses on a personalized approach in which treatment plans are based on the results of specific tests
Because asbestos has been used all over the world, malignant pleural mesothelioma has become a global problem. The search for effective treatments is being conducted all over the world, and researchers from the Hyogo College of Medicine recently shared positive results from a study of an inhalable gene therapy.
Robotic surgery represents one of the most innovative breakthroughs for treating patients with malignant pleural mesothelioma. Its development has provided new options for patients whose tumors were so inaccessible that they would previously have been referred for palliative care. In the skilled hands of some of the world’s most accomplished thoracic surgeons, minimally invasive robotic
Dr. Anthony W. Kim is an internationally respected thoracic oncologist and surgeon. He leads the thoracic surgery division and program at Keck Medicine of University of Southern California and at the USC Norris Comprehensive Cancer Center. He is an expert in thoracic oncology, including in treating malignant pleural mesothelioma and lung cancer, specializing in minimally
Dr. Scott M. Atay specializes in thoracic surgery with an emphasis on malignant diseases including pleural mesothelioma, lung cancer, and esophageal cancer. Committed to delivering compassionate, high-quality care driven by the most up-to-date scientific evidence, he prioritizes offering patients with both early and advanced-stage disease multimodality treatment that combines surgery with chemotherapy, immunotherapy, and radiation
The Massachusetts Attorney General’s Office has issued 104 indictments to a developer it fears raised the risk of malignant mesothelioma to thousands. The company is accused of illegally demolishing a former elementary school, spreading asbestos dust to a large neighborhood and exposing its own workers to the carcinogenic material at the same time.
Dr. Matthew A. Gubens is a thoracic oncologist at the UCSF Thoracic Surgery and Oncology Clinic at the Helen Diller Family Comprehensive Cancer Center. He specializes in treating patients diagnosed with non-small cell lung cancer, small cell lung cancer, thymoma and thymic carcinoma, and malignant pleural mesothelioma. Dr. Gubens is actively involved in research seeking
Dr. Hitesh Batra is an interventional pulmonologist with special interest in pleural diseases, including malignant pleural mesothelioma. He is Director of the University of Alabama at Birmingham Hospital’s Interventional Pulmonology and Pleural Disease program, the state’s first and only interventional pulmonary program. Partnering with a multidisciplinary team of physicians and other healthcare professionals, he offers